Symbols

RLMD

Relmada Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 1

Consensus Rating "Buy"

MACD Golden Cross

Ample Liquidity

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About RLMD

Relmada Therapeutics, Inc.

A late-stage biotechnology company that addressing diseases of the central nervous system

Industry

Pharmaceutical

Established Date

Listing Date

10/10/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.relmada.com

Security Type

Common stock

Office address

2222 Ponce de Leon Blvd., Floor 3, Coral Gables, FL 33134

Business

Introduction

Relmada Therapeutics, Inc., was incorporated under the laws of the State of Nevada. The company is a publicly traded clinical-stage biotechnology company that has shifted its strategic focus following a review of its development programs. It is advancing its R&D pipeline through licensing introductions and acquisitions, including a Phase 2 bladder cancer drug candidate and a neurosteroid for neurological and metabolic diseases ready to enter Phase 2 b.

Company Financials

EPS

RLMD has released its 2025 Q4 earnings. EPS was reported at -0.27, versus the expected -0.17, missing expectations. The chart below visualizes how RLMD has performed over recent quarters, highlighting trends in earnings surprises.